As of Q3'25, AbbVie's latest reported operating cash flow stands at USD 7.02B, while free cash flow is USD 6.64B. These figures mark a significant rebound from the previous quarter, where both metrics were notably lower at USD 5.15B for operating cash flow and USD 4.88B for free cash flow. Over the period from Q1'23 to Q3'25, AbbVie's cash flow performance has exhibited considerable volatility, with both operating and free cash flows experiencing sharp fluctuations. After peaking in Q3'23 (operating: USD 7.57B, free: USD 7.36B), both metrics declined through early 2024, reaching their lowest points in Q1'25 (operating: USD 1.64B, free: USD 1.40B). The strong recovery in Q2'25 and Q3'25 suggests a return to higher cash generation levels, but the overall trend highlights significant quarter-to-quarter variability rather than consistent growth or decline.